The global blood screening market was valued at US$2.3 billion in 2022 and reached US$2.4 billion in 2023. It is projected to advance at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2028, reaching an estimated valuation of US$3.4 billion by the end of the forecast period. This growth is primarily fueled by the increasing volume of blood donations worldwide and the rising prevalence of infectious diseases necessitating rigorous testing protocols.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042

What are the key drivers influencing the growth of the Market?

A primary driver for the blood screening market is the increasing number of blood donations worldwide, necessitated by advancements in healthcare and the rising demand for sophisticated surgical procedures. Major surgeries, including cardiovascular, transplant, and trauma-related operations, alongside therapies for cancer and blood diseases, have significantly escalated the requirement for safe, donated blood. Globally, approximately 235 million major surgeries are performed annually, many of which require blood transfusions to manage complications such as acute anemia or maternal blood disorders.

Additionally, the growing incidence of infectious diseases acts as a major contributor to market expansion. As health authorities and providers prioritize the safety of the global blood supply, the adoption of sensitive screening technologies becomes essential to prevent the transmission of pathogens during transfusions. This trend is further supported by the increasing awareness of blood verification and safety standards across both developed and developing healthcare systems.

What are the major restraints limiting the growth of the Market?

The global market faces significant restraints due to unfavorable reimbursement scenarios and the high costs associated with advanced screening instruments and kits. In many regions, the financial burden of implementing high-end technology limits the ability of healthcare facilities to upgrade from legacy systems. These economic factors can slow the adoption of more effective, yet more expensive, screening solutions, particularly in budget-constrained environments.

The emergence of alternative technologies, such as computerized, single-step immunoassays that do not require washing steps, also presents a restraint. These newer methods offer rapid and highly sensitive quantitative analysis, which can divert interest and investment away from traditional ELISA-based or established molecular screening platforms. Such innovations are particularly attractive for specific applications like serological testing, where speed and minimal invasiveness are highly valued.

What emerging opportunities are expected to shape the future of the Market?

Emerging markets in India, the Middle East, and Africa offer substantial growth opportunities for industry players. These regions are experiencing rising disposable incomes and significant improvements in healthcare infrastructure. For example, the expansion of India’s healthcare sector, driven by increased health awareness and the rising prevalence of lifestyle diseases, creates a fertile environment for the adoption of more advanced blood screening technologies as penetration for methods like Nucleic Acid Testing (NAT) increases.

Furthermore, government-led initiatives in these emerging economies to educate healthcare professionals and blood banks on the benefits of advanced testing present a clear pathway for market development. As these countries transition from older technologies like ELISA to more sensitive molecular methods, there is a significant opening for providers to establish a strong presence and capitalize on the growing demand for modernized blood safety infrastructure.

What are the critical challenges faced by stakeholders in the Market?

One of the most critical challenges is the high cost of advanced blood screening technologies, which inhibits their widespread adoption in middle- and low-income countries. While high-income nations have successfully integrated sophisticated systems, many developing countries continue to rely on first-generation ELISA tests due to the prohibitive pricing of advanced cartridges and molecular platforms. This creates a disparity in blood safety standards and limits the market potential for premium technology providers in these regions.

Additionally, stakeholders must navigate the complexities of varying regulatory requirements and the need for specialized training to operate advanced systems. The lack of mandatory testing for certain advanced technologies in large markets like India means that adoption remains voluntary and fragmented. Overcoming these barriers requires a combination of technological downsizing, cost reduction, and sustained advocacy for standardized global blood safety regulations.

Who are the leading players operating in the Market?

The market is dominated by several key global players, including F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), and Bio-Rad Laboratories, Inc. (US). These companies maintain their leadership through comprehensive product portfolios, significant research and development budgets, and extensive global distribution networks. Other prominent entities include Danaher (US), bioMérieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), and DiaSorin (Italy).

Market leaders are increasingly focusing on strategic acquisitions to expand their molecular diagnostics capabilities. Recent developments include Thermo Fisher Scientific’s acquisition of TIB Molbiol to enhance its PCR test portfolio and Roche Diagnostics’ acquisition of the TIB Molbiol Group to broaden its infectious disease assay offerings. These moves indicate a trend toward consolidation and a focus on high-volume, automated molecular testing solutions.

What are the key segments of the Market based on type, application, and end user?

By product and service, the market is led by the reagents and kits segment, which accounted for the largest share in 2022. This dominance is attributed to the recurring need for consumables driven by the rising number of blood transfusions. The technology segment is dominated by Nucleic Acid Testing (NAT), which is favored for its superior sensitivity compared to traditional serology/immunoassay, rapid tests, and western blot assays.

In terms of end users, the blood banks and hospitals segments hold the largest market shares. Blood banks, in particular, dominated in 2022 due to the increasing volume of organ transplants and the high throughput of donations requiring screening. The market is further categorized by technology into transcription-mediated amplification and real-time PCR, and by product into rental and outright purchase options for instruments.

Which regions are dominating and emerging in the Market?

North America is currently the largest regional market for the blood screening industry. Its leadership is supported by a well-developed healthcare system, high healthcare spending, and a rising prevalence of chronic conditions that necessitate frequent blood transfusions. The United States, in particular, benefits from established safety protocols and advanced infrastructure for blood services.

The Asia Pacific region is emerging as a high-growth market, with countries like China and India seeing significant investments from both domestic and international players. While Europe remains a strong market with key players in Germany, the UK, and France, the rapid infrastructure development and increasing patient affordability in the Asia Pacific and Latin American regions are expected to drive the next phase of global market expansion.

Inquire Before Buying-https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=267747042